These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8752936)

  • 41. Redirected cytotoxic effector function. Requirements for expression of chimeric single chain high affinity immunoglobulin e receptors.
    Kershaw MH; Darcy PK; Hulett MD; Hogarth PM; Trapani JA; Smyth MJ
    J Biol Chem; 1996 Aug; 271(35):21214-20. PubMed ID: 8702893
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A test for clonal relatedness in a set of lymphocytes.
    Litwin S; Shlomchik M
    J Exp Med; 1990 Jan; 171(1):293-7. PubMed ID: 2295879
    [No Abstract]   [Full Text] [Related]  

  • 43. Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects.
    Wang Y; Buck A; Piel B; Zerefa L; Murugan N; Coherd CD; Miklosi AG; Johal H; Bastos RN; Huang K; Ficial M; Laimon YN; Signoretti S; Zhong Z; Hoang SM; Kastrunes GM; Grimaud M; Fayed A; Yuan HC; Nguyen QD; Thai T; Ivanova EV; Paweletz CP; Wu MR; Choueiri TK; Wee JO; Freeman GJ; Barbie DA; Marasco WA
    Mol Cancer; 2024 Mar; 23(1):56. PubMed ID: 38491381
    [TBL] [Abstract][Full Text] [Related]  

  • 44. From bench to bedside: the history and progress of CAR T cell therapy.
    Mitra A; Barua A; Huang L; Ganguly S; Feng Q; He B
    Front Immunol; 2023; 14():1188049. PubMed ID: 37256141
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma.
    Zhang C; Fang L; Wang X; Yuan S; Li W; Tian W; Chen J; Zhang Q; Zhang Y; Zhang Q; Zheng J
    Mol Ther Oncolytics; 2022 Mar; 24():14-25. PubMed ID: 34977339
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Landscape of Immunotherapy in Genitourinary Malignancies.
    Ravindranathan D; Alhalabi O; Rafei H; Shah AY; Bilen MA
    Adv Exp Med Biol; 2021; 1342():143-192. PubMed ID: 34972965
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Self-Assembled Multivalent Aptamer Nanoparticles with Potential CAR-like Characteristics Could Activate T Cells and Inhibit Melanoma Growth.
    Bai C; Gao S; Hu S; Liu X; Li H; Dong J; Huang A; Zhu L; Zhou P; Li S; Shao N
    Mol Ther Oncolytics; 2020 Jun; 17():9-20. PubMed ID: 32280743
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.
    Braendstrup P; Levine BL; Ruella M
    Cytotherapy; 2020 Feb; 22(2):57-69. PubMed ID: 32014447
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis.
    Zhou H; Luo Y; Zhu S; Wang X; Zhao Y; Ou X; Zhang T; Ma X
    BMC Cancer; 2018 Sep; 18(1):929. PubMed ID: 30257649
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.
    Kim M; Pyo S; Kang CH; Lee CO; Lee HK; Choi SU; Park CH
    PLoS One; 2018; 13(6):e0198347. PubMed ID: 29874279
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CAR-T cells: the long and winding road to solid tumors.
    D'Aloia MM; Zizzari IG; Sacchetti B; Pierelli L; Alimandi M
    Cell Death Dis; 2018 Feb; 9(3):282. PubMed ID: 29449531
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adoptive T-Cell Therapy for Solid Tumors.
    Yeku O; Li X; Brentjens RJ
    Am Soc Clin Oncol Educ Book; 2017; 37():193-204. PubMed ID: 28561728
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.
    Junghans RP
    Cancer Gene Ther; 2017 Mar; 24(3):89-99. PubMed ID: 28392558
    [No Abstract]   [Full Text] [Related]  

  • 54. Cellular immunotherapy for malignant gliomas.
    Lin Y; Okada H
    Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy.
    Maus MV; June CH
    Clin Cancer Res; 2016 Apr; 22(8):1875-84. PubMed ID: 27084741
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.
    Lamers CH; Sleijfer S; van Steenbergen S; van Elzakker P; van Krimpen B; Groot C; Vulto A; den Bakker M; Oosterwijk E; Debets R; Gratama JW
    Mol Ther; 2013 Apr; 21(4):904-12. PubMed ID: 23423337
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells.
    Maher J
    ISRN Oncol; 2012; 2012():278093. PubMed ID: 23304553
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Passive immunotherapeutic strategies for the treatment of malignant gliomas.
    Nagasawa DT; Fong C; Yew A; Spasic M; Garcia HM; Kruse CA; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):481-95. PubMed ID: 22748660
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
    Till BG; Jensen MC; Wang J; Qian X; Gopal AK; Maloney DG; Lindgren CG; Lin Y; Pagel JM; Budde LE; Raubitschek A; Forman SJ; Greenberg PD; Riddell SR; Press OW
    Blood; 2012 Apr; 119(17):3940-50. PubMed ID: 22308288
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ex vivo gene transfer for improved adoptive immunotherapy of cancer.
    Ngo MC; Rooney CM; Howard JM; Heslop HE
    Hum Mol Genet; 2011 Apr; 20(R1):R93-9. PubMed ID: 21415041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.